Data as of Aug 21
| -0.07 / -1.22%|
The 5 analysts offering 12-month price forecasts for Avanir Pharmaceuticals Inc have a median target of 10.00, with a high estimate of 13.00 and a low estimate of 5.00. The median estimate represents a +76.68% increase from the last price of 5.66.
The current consensus among 5 polled investment analysts is to Buy stock in Avanir Pharmaceuticals Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.